Chalandon Y, Thomas X, Hayette S, et al; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125(24):3711-3719.

doi:10.1182/blood-2015-07-660480

Skip Nav Destination

ERRATA| September 3, 2015

Chalandon Y, Thomas X, Hayette S, et al; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125(24):3711-3719.

Blood (2015) 126 (10): 1261.

https://doi.org/10.1182/blood-2015-07-660480

On page 3713 in the 11 June 2015 issue, there are errors in Table 1. The table does not distinguish between the respective doses and schedules for the drugs filgrastim and pegfilgrastim. Also, the schedule for the pre-SCT interphase treatment phase with the drug MTX reads “Days 1-8.” It should read “Days 1 and 8.” The corrected Table 1 is shown below. The errors have been corrected in the online version, which now differs from the print version.

2015

Table 1

GRAAPH-2005 treatments

Treatment phases	Drugs	Doses	Schedules
Initial treatments
Prephase	PDN	60 mg/m²/d po	Day −7 to day −1
	MTX	15 mg IT	Between day −7 and day −4
Cycle 1 arm A	VCR	2 mg/d IV	Days 1, 8, 15, and 22
	DXM	40 mg/d po	Days 1-2, 8-9, 15-16, and 22-23
	Imatinib	400 mg bid po	Days 1-28
	Filgrastim	5 μg/kg/d sc/IV	From day 15 to PMN recovery
Cycle 1 arm B	VCR	2 mg/d IV	Day 4 and day 11
	DXM	40 mg/d po	Days 1-4 and 11-14
	DXR	50 mg/m²/d CIV	Day 4
	CPM	300 mg/m²/12 h IV	Day 1-3
	Imatinib	400 mg bid po	Day 1-14
	Filgrastim or pegfilgrastim	5 μg/kg/d sc/IV (filgrastim) or 6 mg sc (pegfilgrastim)	From day 15 to PMN recovery (filgrastim) or day 6 (pegfilgrastim)
Cycle 2 (both arms)	MTX	1000 mg/m²/d CIV	Day 1
	Ara-C	3000 mg/m²/12 h IV	Days 2-3
	Imatinib	400 mg bid po	Days 1-14
	Filgrastim or pegfilgrastim	5 μg/kg/d sc/IV (filgrastim) or 6 mg sc (pegfilgrastim)	From day 9 to PMN recovery (filgrastim) or day 6 (pegfilgrastim)
Pre-SCT interphase (n = 2)	MTX	25 mg/m²/d po	Days 1 and 8
	6-MP	60 mg/m²/d po	Days 1-14
	Imatinib	300 mg bid po	Days 1-14
Further treatments for non-SCT patients
Cycles 3, 5, and 7	Identical to cycle 1 arm B, with reduced 300 mg imatinib bid from day 1 to day 14
Cycles 4, 6, and 8	Identical to cycle 2, with reduced 300 mg imatinib bid from day 1 to day 14
Monthly maintenance cycles	Replaced at month 6 by a cycle 9 (like cycles 3, 5 and 7) and at month 12 by a cycle 10 (like cycles 4, 6, and 8)
	PDN	200 mg/d po	Days 1-5, months 1-12
	VCR	2 mg/d IV	Day 1, months 1-12
	Imatinib	300 mg bid po	Months 1-24
Post–autologous SCT maintenance
Months 1, 3, 5... to 23	Imatinib	300 mg bid po	For 1 mo
Months 2, 4, 6... to 24	MTX	25 mg/m²/wk po	For 1 mo
	6-MP	60 mg/m²/d po	For 1 mo
CNS treatments
CNS prophylaxis	Triple IT*	n = 1	Days 1, 8, and 15 of cycle 1
	Triple IT	n = 1	Day 9 of cycle 2
	Triple IT	n = 1	Day 1 of the 2 interphase cycles
If initial CNS involvement	Triple IT	n = 8	Between day −7 and day 21 of cycle 1
	Triple IT	n = 1 per wk thereafter	For a total of 12 ITs
	Cranial irradiation	15 Gy before SCT or 24 Gy after cycle 8 in non-SCT patients
	Imatinib	300 mg bid po	During cranial irradiation

Treatment phases	Drugs	Doses	Schedules
Initial treatments
Prephase	PDN	60 mg/m²/d po	Day −7 to day −1
	MTX	15 mg IT	Between day −7 and day −4
Cycle 1 arm A	VCR	2 mg/d IV	Days 1, 8, 15, and 22
	DXM	40 mg/d po	Days 1-2, 8-9, 15-16, and 22-23
	Imatinib	400 mg bid po	Days 1-28
	Filgrastim	5 μg/kg/d sc/IV	From day 15 to PMN recovery
Cycle 1 arm B	VCR	2 mg/d IV	Day 4 and day 11
	DXM	40 mg/d po	Days 1-4 and 11-14
	DXR	50 mg/m²/d CIV	Day 4
	CPM	300 mg/m²/12 h IV	Day 1-3
	Imatinib	400 mg bid po	Day 1-14
	Filgrastim or pegfilgrastim	5 μg/kg/d sc/IV (filgrastim) or 6 mg sc (pegfilgrastim)	From day 15 to PMN recovery (filgrastim) or day 6 (pegfilgrastim)
Cycle 2 (both arms)	MTX	1000 mg/m²/d CIV	Day 1
	Ara-C	3000 mg/m²/12 h IV	Days 2-3
	Imatinib	400 mg bid po	Days 1-14
	Filgrastim or pegfilgrastim	5 μg/kg/d sc/IV (filgrastim) or 6 mg sc (pegfilgrastim)	From day 9 to PMN recovery (filgrastim) or day 6 (pegfilgrastim)
Pre-SCT interphase (n = 2)	MTX	25 mg/m²/d po	Days 1 and 8
	6-MP	60 mg/m²/d po	Days 1-14
	Imatinib	300 mg bid po	Days 1-14
Further treatments for non-SCT patients
Cycles 3, 5, and 7	Identical to cycle 1 arm B, with reduced 300 mg imatinib bid from day 1 to day 14
Cycles 4, 6, and 8	Identical to cycle 2, with reduced 300 mg imatinib bid from day 1 to day 14
Monthly maintenance cycles	Replaced at month 6 by a cycle 9 (like cycles 3, 5 and 7) and at month 12 by a cycle 10 (like cycles 4, 6, and 8)
	PDN	200 mg/d po	Days 1-5, months 1-12
	VCR	2 mg/d IV	Day 1, months 1-12
	Imatinib	300 mg bid po	Months 1-24
Post–autologous SCT maintenance
Months 1, 3, 5... to 23	Imatinib	300 mg bid po	For 1 mo
Months 2, 4, 6... to 24	MTX	25 mg/m²/wk po	For 1 mo
	6-MP	60 mg/m²/d po	For 1 mo
CNS treatments
CNS prophylaxis	Triple IT*	n = 1	Days 1, 8, and 15 of cycle 1
	Triple IT	n = 1	Day 9 of cycle 2
	Triple IT	n = 1	Day 1 of the 2 interphase cycles
If initial CNS involvement	Triple IT	n = 8	Between day −7 and day 21 of cycle 1
	Triple IT	n = 1 per wk thereafter	For a total of 12 ITs
	Cranial irradiation	15 Gy before SCT or 24 Gy after cycle 8 in non-SCT patients
	Imatinib	300 mg bid po	During cranial irradiation

Ara-C, cytarabine; bid, twice daily; CIV, continuous IV; CNS, central nervous system; CPM, cyclophosphamide; DXM, dexamethasone; DXR, doxorubicin; IT, intrathecal; 6-MP, 6-mercaptopurine; MTX, methotrexate; PDN, prednisone; PMN, polymorphonuclear neutrophil; po, by mouth; sc, subcutaneously; VCR, vincristine.

Triple IT consisted of 15 mg MTX, 40 mg Ara-C, and 40 mg PDN.

Chalandon Y, Thomas X, Hayette S, et al; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125(24):3711-3719.

Contents

Data & Figures

Supplemental data

References

Cited By

Email alerts

ASH Publications

American Society of Hematology

Chalandon Y, Thomas X, Hayette S, et al; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125(24):3711-3719.

Contents

Data & Figures

Supplemental data

References

Related

Related

Cited By

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only